Last updated: February 13, 2026
What is the current market position of NDC 78206-0113?
NDC 78206-0113 corresponds to Rucaparib (Rubraca), an oral PARP inhibitor approved by the FDA for the treatment of ovarian cancer and other BRCA-mutated cancers. The drug entered the US market in December 2016, with subsequent approvals for various indications, including ovarian, prostate, and breast cancers.
What are the key market dynamics impacting Rucaparib?
Market Size and Demand
- The global ovarian cancer therapeutics market was valued at approximately $4.8 billion in 2022.
- Rucaparib's sales in the US were estimated at roughly $250 million in 2022, with increasing adoption driven by its indication expansion.
- The prostate cancer segment is rapidly growing; the approval for metastatic castration-resistant prostate cancer (mCRPC) in 2020 increased market potential.
Competitive Landscape
- Rucaparib competes primarily with Lynparza (olaparib) and Zejula (niraparib).
- Lynparza holds the largest market share, with revenue exceeding $2.3 billion globally in 2022.
- Zejula is also gaining traction, especially for ovarian and breast cancer indications.
Pricing and Reimbursement
- In the US, the wholesale acquisition cost (WAC) for Rucaparib is approximately $17,000 per month.
- Insurance coverage is generally favorable but varies by payer, impacting patient access and sales volume.
Patent Status and Exclusivity
- Rucaparib's primary patent in the US expires around 2030.
- Market exclusivity is influenced by method-of-use patents and potential patent extensions.
What are the projections for Rucaparib's pricing?
Short-term (Next 1-2 years)
- Pricing is likely to remain stable at current levels, with modest increases aligned with inflation and cost adjustments.
- Payer negotiations and formulary placements will influence net revenue.
Medium-term (3-5 years)
- Entry of biosimilars or generics is unlikely due to the nature of small molecule patents, though patent challenges could arise.
- Price reductions of 10-15% are feasible if competitive pressures increase or if new approvals expand the market.
Long-term (Beyond 5 years)
- Potential for price declines as patent protections expire or if healthcare policies shift towards cost containment.
- Innovation in combination therapies could reduce reliance on monotherapy pricing strategies.
What are the key factors influencing future sales and pricing?
| Factor |
Impact |
Details |
| Patent protection |
Maintains pricing power |
Patents until 2030 with potential extensions |
| Competitive dynamics |
Caps upside if rivals gain market share |
Lynparza's dominance and Zejula's growth |
| Market expansion |
Increases revenue opportunities |
Approvals in prostate and breast cancers |
| Healthcare policy |
Potential price controls |
US government initiatives promoting generics |
| Clinical trial results |
May expand or limit indications |
Positive outcomes can boost usage or value |
What are the regulatory and policy implications?
- The FDA continues to approve new indications for PARP inhibitors, potentially impacting Rucaparib's market share.
- The Inflation Reduction Act and other policy measures might influence drug pricing strategies.
- Bioequivalence pathways and patent litigations could alter future market exclusivity.
Summary of projections
| Year |
Projected US Sales |
Approximate Price per Cycle |
Commentary |
| 2023 |
$300 million |
$17,000 per month (~$51,000 per cycle) |
Stable pricing; increasing utilization in expanded indications. |
| 2025 |
$400-500 million |
Similar or slightly increased |
Market expansion and new approvals drive growth. |
| 2028 |
$500-600 million |
Possible 10-15% price reduction |
Market maturity with increased competition; patent protections still active. |
Key Takeaways
- Rucaparib remains a significant player in the PARP inhibitor class, with US sales around $250 million in 2022.
- Competitive pressures, patent protections, and regulatory changes will shape pricing over the next five years.
- Market expansion into prostate and breast cancer indications offers growth but hinges on further clinical success and approval.
- Pricing likely to stabilize short-term, with modest reductions possible long-term due to patent expiry and healthcare policies.
- The competitive landscape favors Lynparza, which holds a larger market share and higher revenue, impacting Rucaparib's growth trajectory.
FAQs
1. How does Rucaparib's pricing compare to its competitors?
Rucaparib's monthly WAC at approximately $17,000 is similar to Lynparza's and Zejula's prices, though actual negotiated net prices may vary significantly.
2. What is the expected timeline for patent expiration?
Primary patents cover until 2030, with potential extensions through filings and patent litigation.
3. Can biosimilars or generics impact Rucaparib's market?
Since Rucaparib is a small molecule, generic competition is possible post-patent expiry, but current patent protections delay this.
4. How do clinical trial outcomes influence Rucaparib pricing?
Positive trial results that expand indications can increase demand, supporting stable or higher pricing; negative results could diminish its value.
5. What regulatory changes could affect Rucaparib's market?
Any moves to cap drug prices or facilitate biosimilar entry could reduce prices and market share.
Sources:
[1] IQVIA, "Prescription Drug Market Data," 2022.
[2] Food and Drug Administration (FDA), "Rucaparib NDA Approval," 2016.
[3] EvaluatePharma, "Cancer Drugs Market Overview," 2022.
[4] U.S. Healthcare Policy Reports, 2023.
